JPRN-UMIN000036039招募中未知
Effects of Ipragliflozin on Body Composition in Type 1 Diabetic Patients - Effects of Ipragliflozin on Body Composition in Type 1 Diabetic Patients
Ise Red Cross Hospital Department of Metabolic Diseases0 个研究点目标入组 50 人开始时间: 2019年3月1日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 招募中
- 发起方
- 入组人数
- 50
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- 20years-old 至 75years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •Patients who had ketoacidosis or coma Malignancies or other diseases with poor prognosis eGFR<60mL/min/1.73m2
研究者
相似试验
已完成
不适用
Effects of ipragliflozin on body composition and beta-cell function in Japanese patients with type 2 diabetesType 2 diabetesJPRN-UMIN000021623St. Marianna University School of Medicine20
尚未招募
不适用
The effect of tofogliflozin on body fat volumeType 2 diabetesJPRN-UMIN000036013Tokushima University Graduate School15
已完成
不适用
Effects of ipragliflozin on nonalcoholic fatty liver disease in patients with type 2 diabetesType 2 diabetes with nonalcoholic fatty liver diseaseJPRN-UMIN000022651Ogawa Red Cross Hospital60
已完成
不适用
ong-term effects of ipragliflozin on nonalcoholic fatty liver disease in patients with type 2 diabetesType 2 diabetes complicated by NAFLDJPRN-UMIN000040611Ogawa Red Cross Hospital66
已完成
不适用
Efficacy and safety of Ipragliflozin in patients with type 2 diabetes who have inadequate glycemic control.Type 2 diabetesJPRN-UMIN000014306akakinen clinic100